Creative Medical Technology Holdings Inc (CELZ)

$2.00 -0.08 (-3.85%)
Market Cap 5.21M
Revenue (ttm) 10,000.00
Net Income (ttm) -5.49M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -54,900.00%
Debt to Equity Ratio 0.00
Volume 17,600
Avg Vol 114,258
Day's Range N/A - N/A
Shares Out 2.58M
Stochastic %K 19%
Beta 2.08
Analysts Sell
Price Target $20.00

Company Profile

Creative Medical Technology Holdings, Inc., a commercial-stage biotechnology company, focuses on novel biological therapeutics in the fields of immunotherapy, endocrinology, urology, neurology, and orthopedics in the United States. The company offers CaverStem to treat erectile dysfunction, and FemCelz for the treatment of loss of genital sensitivity and dryness. It develops AlloStem (CELZ-201-DDT), a allogenic human perinatal tissue derived cell program, ImmCelz (CELZ-100), a personalized super...

Industry: Biotechnology
Sector: Healthcare
Phone: 480 399 2822
Address:
211 East Osborn Road, Phoenix, United States
Eddie_Hex
Eddie_Hex Feb. 3 at 2:56 PM
$CELZ Or was it....
0 · Reply
CG2260
CG2260 Feb. 3 at 11:11 AM
$CELZ premarket increase seems like a glitch
0 · Reply
Eddie_Hex
Eddie_Hex Feb. 3 at 10:41 AM
$CELZ
0 · Reply
tonneke
tonneke Feb. 3 at 10:39 AM
$CELZ 💪💪💪
0 · Reply
Eddie_Hex
Eddie_Hex Jan. 30 at 10:52 AM
$CELZ Tick tock tick tock...
1 · Reply
Peterb3346
Peterb3346 Jan. 28 at 2:01 PM
$CELZ just a matter of time before this breaks out like Spruce Biosciences did.
1 · Reply
Bobby_J_Bomb
Bobby_J_Bomb Jan. 22 at 10:59 PM
$CELZ which gap do we fill on the next run?
0 · Reply
HODLnCaulfield
HODLnCaulfield Jan. 22 at 9:21 PM
$CELZ added.
0 · Reply
Peterb3346
Peterb3346 Jan. 22 at 8:26 PM
$CELZ more is coming.
0 · Reply
wokazn
wokazn Jan. 22 at 4:40 PM
$CELZ in the back trial, they started with the low dose cohorts first. Not sure why Tim omitted this information, but the fact is with the higher dose cohorts, this group will most likely see even stronger outcomes. But again, even the low dose group had great results!
1 · Reply
Latest News on CELZ
Creative Medical Technology Holdings Reaches Major Clinical Inflection Point with Positive Interim Data from ADAPT Trial and CELZ-201 (Olastrocel) in the Treatment of Chronic Lower Back Pain

Jan 13, 2026, 9:15 AM EST - 21 days ago

Creative Medical Technology Holdings Reaches Major Clinical Inflection Point with Positive Interim Data from ADAPT Trial and CELZ-201 (Olastrocel) in the Treatment of Chronic Lower Back Pain

Creative Medical Technology Holdings Receives Regulatory Approval for BioDefense Burn Pit Initiative

Jan 6, 2026, 9:15 AM EST - 4 weeks ago

Creative Medical Technology Holdings Receives Regulatory Approval for BioDefense Burn Pit Initiative

Creative Medical Technology Holdings, Inc. Completes Enrollment in FDA-Cleared ADAPT Trial for CELZ-201-Olastrocel, Marking Major Clinical Inflection Point

Dec 17, 2025, 9:15 AM EST - 6 weeks ago

Creative Medical Technology Holdings, Inc. Completes Enrollment in FDA-Cleared ADAPT Trial for CELZ-201-Olastrocel, Marking Major Clinical Inflection Point

Creative Medical Technology Holdings Announces World Health Organization Approval of “olastrocel” as INN for Lead Allogeneic Cell Therapy CELZ-201

Dec 2, 2025, 9:15 AM EST - 2 months ago

Creative Medical Technology Holdings Announces World Health Organization Approval of “olastrocel” as INN for Lead Allogeneic Cell Therapy CELZ-201

Creative Medical Technology Holdings, Inc. Ignites Next-Gen Regenerative BioDefense Initiative for U.S. Veterans Exposed to Burn Pits

Oct 30, 2025, 9:15 AM EDT - 3 months ago

Creative Medical Technology Holdings, Inc. Ignites Next-Gen Regenerative BioDefense Initiative for U.S. Veterans Exposed to Burn Pits

Creative Medical Technology Holdings Announces Agreements for Exercise of Warrants for $4.2 Million Gross Proceeds

Oct 29, 2025, 9:00 AM EDT - 3 months ago

Creative Medical Technology Holdings Announces Agreements for Exercise of Warrants for $4.2 Million Gross Proceeds

Creative Medical Technology Holdings Issues Letter to Shareholders

Oct 27, 2025, 8:15 AM EDT - 3 months ago

Creative Medical Technology Holdings Issues Letter to Shareholders

Creative Medical Technology Holdings Congratulates 2025 Nobel Laureates for Regulatory T Cell Breakthroughs

Oct 7, 2025, 9:15 AM EDT - 4 months ago

Creative Medical Technology Holdings Congratulates 2025 Nobel Laureates for Regulatory T Cell Breakthroughs

Creative Medical Technology Holdings Receives Notice of Allowance for the Prevention and/or Treatment of Type 1 Diabetes Using Modulated Immune Cells

Jul 17, 2025, 9:15 AM EDT - 7 months ago

Creative Medical Technology Holdings Receives Notice of Allowance for the Prevention and/or Treatment of Type 1 Diabetes Using Modulated Immune Cells

Creative Medical Technology Holdings Receives Notice of Allowance for ImmCelz™ for Treatment of Heart Failure and/or Post Infarct Pathological Remodeling

Jul 11, 2025, 8:01 AM EDT - 7 months ago

Creative Medical Technology Holdings Receives Notice of Allowance for ImmCelz™ for Treatment of Heart Failure and/or Post Infarct Pathological Remodeling

Creative Medical Technology Holdings Secures FDA Clearance for Expanded Dose Escalation in the Clinical Trial of CELZ-201-DDT for Chronic Lower Back Pain

Mar 20, 2025, 7:50 AM EDT - 11 months ago

Creative Medical Technology Holdings Secures FDA Clearance for Expanded Dose Escalation in the Clinical Trial of CELZ-201-DDT for Chronic Lower Back Pain

Creative Medical Technology Holdings Announces Agreements for Exercise of Warrants for $3.7 Million Gross Proceeds

Mar 6, 2025, 8:10 AM EST - 11 months ago

Creative Medical Technology Holdings Announces Agreements for Exercise of Warrants for $3.7 Million Gross Proceeds

Creative Medical Technology Holdings Announces Mid-Term Follow-up Study Data Reporting Significant Reduction in Opioid Use by Chronic Lower Back Pain Patients Undergoing StemSpine® Procedure using AlloStem™

Feb 14, 2025, 7:00 AM EST - 1 year ago

Creative Medical Technology Holdings Announces Mid-Term Follow-up Study Data Reporting Significant Reduction in Opioid Use by Chronic Lower Back Pain Patients Undergoing StemSpine® Procedure using AlloStem™

Creative Medical Technology Reports Positive One-Year Results for AlloStem™ Type 2 Diabetes Program

Feb 11, 2025, 9:25 AM EST - 1 year ago

Creative Medical Technology Reports Positive One-Year Results for AlloStem™ Type 2 Diabetes Program

Creative Medical Technology Holdings Expands Collaboration with Greenstone Biosciences to Accelerate iPSCelz Pipeline Development

Feb 5, 2025, 8:25 AM EST - 1 year ago

Creative Medical Technology Holdings Expands Collaboration with Greenstone Biosciences to Accelerate iPSCelz Pipeline Development

Creative Medical Technology Holdings Announces Positive Initial Safety, Tolerability, and Efficacy Data from First Cohort in Phase 1/2 Trial of CELZ-201-DDT for Chronic Back Pain

Jan 30, 2025, 9:25 AM EST - 1 year ago

Creative Medical Technology Holdings Announces Positive Initial Safety, Tolerability, and Efficacy Data from First Cohort in Phase 1/2 Trial of CELZ-201-DDT for Chronic Back Pain

Creative Medical Technology Holdings, Inc. Advances FDA Cleared ADAPT Clinical Trial with Positive Independent Review, Validating the Safety and Potential of CELZ-201 for Chronic Lower Back Pain Treatment

Nov 13, 2024, 9:00 AM EST - 1 year ago

Creative Medical Technology Holdings, Inc. Advances FDA Cleared ADAPT Clinical Trial with Positive Independent Review, Validating the Safety and Potential of CELZ-201 for Chronic Lower Back Pain Treatment

Creative Medical Technology Holdings Initiates Development of AI-Driven Diagnostic and Treatment Program for Biologic and Chemical Exposure Utilizing its Validated iPSC Personalized Medicine Program

Jul 24, 2024, 9:00 AM EDT - 1 year ago

Creative Medical Technology Holdings Initiates Development of AI-Driven Diagnostic and Treatment Program for Biologic and Chemical Exposure Utilizing its Validated iPSC Personalized Medicine Program

Creative Medical Technology Holdings Provides Corporate Update

Jul 10, 2024, 8:30 AM EDT - 1 year ago

Creative Medical Technology Holdings Provides Corporate Update

Creative Medical Technology Holdings Announces Evolutionary Development of its iPSCelz® Program with the Successful Generation of iPSC Derived Islet Cells that Produce Human Insulin

Jun 24, 2024, 8:30 AM EDT - 1 year ago

Creative Medical Technology Holdings Announces Evolutionary Development of its iPSCelz® Program with the Successful Generation of iPSC Derived Islet Cells that Produce Human Insulin

Creative Medical Technology Holdings Inc. Announces FDA Authorization for Groundbreaking Type 1 Diabetes Prevention Therapy Under Expanded Access

Mar 7, 2024, 9:15 AM EST - 2 years ago

Creative Medical Technology Holdings Inc. Announces FDA Authorization for Groundbreaking Type 1 Diabetes Prevention Therapy Under Expanded Access

Creative Medical Technology Holdings, Inc. Receives FDA Orphan Drug Designation for CELZ-101 in Key Transplantation Therapy

Mar 6, 2024, 7:00 AM EST - 2 years ago

Creative Medical Technology Holdings, Inc. Receives FDA Orphan Drug Designation for CELZ-101 in Key Transplantation Therapy

Creative Medical Technology Holdings (NASDAQ:CELZ) Granted FDA Clearance To Begin Phase 1/2 Clinical Trial Of AlloStem(TM) For Addressing Chronic Lower Back Pain

Dec 20, 2023, 9:35 AM EST - 2 years ago

Creative Medical Technology Holdings (NASDAQ:CELZ) Granted FDA Clearance To Begin Phase 1/2 Clinical Trial Of AlloStem(TM) For Addressing Chronic Lower Back Pain

Creative Medical Technology Holdings Announces IRB Approval for FDA Cleared Phase 1/2 Clinical Trial of StemSpine® using AlloStem™ ("CELZ-201-DDT") Novel Cell Therapy to Treat Chronic Lower Back Pain

Oct 10, 2023, 8:00 AM EDT - 2 years ago

Creative Medical Technology Holdings Announces IRB Approval for FDA Cleared Phase 1/2 Clinical Trial of StemSpine® using AlloStem™ ("CELZ-201-DDT") Novel Cell Therapy to Treat Chronic Lower Back Pain

Creative Medical Technology Holdings Receives FDA Clearance to Initiate a Phase 1/2 Clinical Trial of StemSpine® using AlloStem™ (CELZ-201-DDT) for the Treatment of Chronic Lower Back Pain

Sep 19, 2023, 8:00 AM EDT - 2 years ago

Creative Medical Technology Holdings Receives FDA Clearance to Initiate a Phase 1/2 Clinical Trial of StemSpine® using AlloStem™ (CELZ-201-DDT) for the Treatment of Chronic Lower Back Pain

What Is Allogeneic Cell Therapy, And What's Driving This Market's 25%+ Annual Global Growth?

Aug 24, 2023, 10:45 AM EDT - 2 years ago

What Is Allogeneic Cell Therapy, And What's Driving This Market's 25%+ Annual Global Growth?

The Immunotherapy Market is Expected to Surpass $351.56 Billion by 2030 - Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ) is Contributing to this Growth

Jul 14, 2023, 9:00 AM EDT - 2 years ago

The Immunotherapy Market is Expected to Surpass $351.56 Billion by 2030 - Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ) is Contributing to this Growth

Creative Medical Technology Reports Advancements In Regenerative Medicine And Improvements In Financial Position In Corporate Update

Jul 13, 2023, 9:00 AM EDT - 2 years ago

Creative Medical Technology Reports Advancements In Regenerative Medicine And Improvements In Financial Position In Corporate Update

Creative Medical Technology Holdings Regains Compliance With Nasdaq Listing Requirements

Jun 28, 2023, 8:00 AM EDT - 2 years ago

Creative Medical Technology Holdings Regains Compliance With Nasdaq Listing Requirements

Creative Medical Technology Announces $2 Million Share Repurchase Program

Jun 12, 2023, 8:01 AM EDT - 2 years ago

Creative Medical Technology Announces $2 Million Share Repurchase Program

Creative Medical Technology Holdings Announces Reverse Stock Split

Jun 9, 2023, 12:30 PM EDT - 2 years ago

Creative Medical Technology Holdings Announces Reverse Stock Split

Creative Medical Technology Holdings Announces Successful Completion of the First Phase of its Program with Greenstone Biosciences, Inc. to Develop Next Generation iPSC Pipeline for ImmCelz® Immunotherapy Platform

May 31, 2023, 8:00 AM EDT - 2 years ago

Creative Medical Technology Holdings Announces Successful Completion of the First Phase of its Program with Greenstone Biosciences, Inc. to Develop Next Generation iPSC Pipeline for ImmCelz® Immunotherapy Platform

Creative Medical Technology Holdings Announces Next Milestone Achievements in ImmCelz® Platform Development

May 22, 2023, 8:30 AM EDT - 2 years ago

Creative Medical Technology Holdings Announces Next Milestone Achievements in ImmCelz® Platform Development

Creative Medical Technology Holdings Announces Positive Top-Line Study Results for Chronic Lower Back Pain Utilizing its StemSpine® Procedure Using AlloStem™ Allogenic Cell Line

May 18, 2023, 8:00 AM EDT - 2 years ago

Creative Medical Technology Holdings Announces Positive Top-Line Study Results for Chronic Lower Back Pain Utilizing its StemSpine® Procedure Using AlloStem™ Allogenic Cell Line

Creative Medical Technology Announces Positive Top-Line Results for Type 2 Diabetes Study

Apr 12, 2023, 8:00 AM EDT - 3 years ago

Creative Medical Technology Announces Positive Top-Line Results for Type 2 Diabetes Study

Creative Medical Technology Holdings Announces Filing of 2022 Form 10-K and Provides Business Update

Apr 4, 2023, 8:00 AM EDT - 3 years ago

Creative Medical Technology Holdings Announces Filing of 2022 Form 10-K and Provides Business Update

Creative Medical Technology Files Orphan Drug Designation Application with the U.S. FDA Using the ImmCelz® Platform for the Treatment of Brittle Type 1 Diabetes

Mar 23, 2023, 8:00 AM EDT - 3 years ago

Creative Medical Technology Files Orphan Drug Designation Application with the U.S. FDA Using the ImmCelz® Platform for the Treatment of Brittle Type 1 Diabetes

Creative Medical Technology Holdings Announces Key Milestones Regarding ImmCelz® Platform Development

Mar 21, 2023, 8:00 AM EDT - 3 years ago

Creative Medical Technology Holdings Announces Key Milestones Regarding ImmCelz® Platform Development

Creative Medical Technology Holdings Engages Highly Respected International CRO for Phase 1 / 2 Clinical Trial to Treat Type 1 Diabetes Using CELZ-201

Mar 7, 2023, 8:00 AM EST - 3 years ago

Creative Medical Technology Holdings Engages Highly Respected International CRO for Phase 1 / 2 Clinical Trial to Treat Type 1 Diabetes Using CELZ-201

Three Year Follow-Up Results Confirm Efficacy of StemSpine® Procedure for Treating Chronic Lower Back Pain, with No Serious Adverse Effects

Feb 14, 2023, 8:00 AM EST - 3 years ago

Three Year Follow-Up Results Confirm Efficacy of StemSpine® Procedure for Treating Chronic Lower Back Pain, with No Serious Adverse Effects

Creative Medical Technology Holdings Announces IRB Approval for FDA Cleared Phase 1/2 Clinical Trial of Novel Cell Therapy for the Treatment of Type 1 Diabetes

Feb 8, 2023, 8:00 AM EST - 3 years ago

Creative Medical Technology Holdings Announces IRB Approval for FDA Cleared Phase 1/2 Clinical Trial of Novel Cell Therapy for the Treatment of Type 1 Diabetes

Creative Medical Technology Holdings Announces FDA Clearance of Investigational New Drug (IND) Application for AlloStem™, a Novel Cell Therapy for the Treatment of Type 1 Diabetes

Nov 3, 2022, 7:30 AM EDT - 3 years ago

Creative Medical Technology Holdings Announces FDA Clearance of Investigational New Drug (IND) Application for AlloStem™, a Novel Cell Therapy for the Treatment of Type 1 Diabetes

Creative Medical Technology Holdings Develops AlloStem™ Clinical Cell Line

Oct 20, 2022, 8:00 AM EDT - 3 years ago

Creative Medical Technology Holdings Develops AlloStem™ Clinical Cell Line

Creative Medical Technology Announces Peer Reviewed Publication of Positive Results for StemSpine® Study

Sep 26, 2022, 8:00 AM EDT - 3 years ago

Creative Medical Technology Announces Peer Reviewed Publication of Positive Results for StemSpine® Study

Creative Medical Technology Announces Positive Top-Line Results for OvaStem® Pilot Study

Jul 28, 2022, 7:30 AM EDT - 3 years ago

Creative Medical Technology Announces Positive Top-Line Results for OvaStem® Pilot Study

Creative Medical Technology Holdings Announces Agreement with Greenstone Biosciences, Inc. for Development of a Next Generation iPSC Pipeline for its ImmCelz® Immunotherapy Platform

Jun 15, 2022, 8:30 AM EDT - 3 years ago

Creative Medical Technology Holdings Announces Agreement with Greenstone Biosciences, Inc. for Development of a Next Generation iPSC Pipeline for its ImmCelz® Immunotherapy Platform

Creative Medical Technology Announces $17 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Apr 29, 2022, 8:40 AM EDT - 4 years ago

Creative Medical Technology Announces $17 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Creative Medical Technology Announces Progress in Developing a Reproducible Clinical Grade of the Company's ImmCelz® Product

Apr 20, 2022, 8:30 AM EDT - 4 years ago

Creative Medical Technology Announces Progress in Developing a Reproducible Clinical Grade of the Company's ImmCelz® Product

Creative Medical Technology to Showcase CaverStem® at American Urological Association Annual Meeting - Largest and Most Prominent Gathering of Urologists in the World

Apr 12, 2022, 8:30 AM EDT - 4 years ago

Creative Medical Technology to Showcase CaverStem® at American Urological Association Annual Meeting - Largest and Most Prominent Gathering of Urologists in the World

Why Creative Medical Technology Shares Are Soaring

Mar 23, 2022, 10:15 AM EDT - 4 years ago

Why Creative Medical Technology Shares Are Soaring

Eddie_Hex
Eddie_Hex Feb. 3 at 2:56 PM
$CELZ Or was it....
0 · Reply
CG2260
CG2260 Feb. 3 at 11:11 AM
$CELZ premarket increase seems like a glitch
0 · Reply
Eddie_Hex
Eddie_Hex Feb. 3 at 10:41 AM
$CELZ
0 · Reply
tonneke
tonneke Feb. 3 at 10:39 AM
$CELZ 💪💪💪
0 · Reply
Eddie_Hex
Eddie_Hex Jan. 30 at 10:52 AM
$CELZ Tick tock tick tock...
1 · Reply
Peterb3346
Peterb3346 Jan. 28 at 2:01 PM
$CELZ just a matter of time before this breaks out like Spruce Biosciences did.
1 · Reply
Bobby_J_Bomb
Bobby_J_Bomb Jan. 22 at 10:59 PM
$CELZ which gap do we fill on the next run?
0 · Reply
HODLnCaulfield
HODLnCaulfield Jan. 22 at 9:21 PM
$CELZ added.
0 · Reply
Peterb3346
Peterb3346 Jan. 22 at 8:26 PM
$CELZ more is coming.
0 · Reply
wokazn
wokazn Jan. 22 at 4:40 PM
$CELZ in the back trial, they started with the low dose cohorts first. Not sure why Tim omitted this information, but the fact is with the higher dose cohorts, this group will most likely see even stronger outcomes. But again, even the low dose group had great results!
1 · Reply
CG2260
CG2260 Jan. 22 at 3:42 PM
$CELZ 52-weeks high soon
0 · Reply
RiZzBoTt
RiZzBoTt Jan. 21 at 3:54 PM
$CELZ starter here. 2.07 average
0 · Reply
_Sensei_
_Sensei_ Jan. 20 at 10:11 PM
$CELZ $5 stock
1 · Reply
Bobby_J_Bomb
Bobby_J_Bomb Jan. 20 at 2:57 PM
$CELZ someone could come in and swoop this up for cheap and get all the IP and patents and build on the progress.
2 · Reply
wokazn
wokazn Jan. 20 at 2:33 PM
$CELZ $IVF 🔥 🚀 Celz with the best treatment! https://1187953.ir365connect.com/pressreleases/detail/f9f625ab-fffa-451a-a94e-2772be99ece0
0 · Reply
Bobby_J_Bomb
Bobby_J_Bomb Jan. 20 at 12:08 PM
$CELZ double bottom with a swing top of $2.45 resistance. Needs to break that to fly sky high.
0 · Reply
tonneke
tonneke Jan. 20 at 8:32 AM
$CELZ Good morning shorts and bulls, hope the bulls win this week 💪
0 · Reply
H177
H177 Jan. 19 at 7:16 PM
$CELZ
0 · Reply
gteu3212
gteu3212 Jan. 19 at 1:22 PM
$CELZ work in progress! 🚀
0 · Reply
H177
H177 Jan. 19 at 8:52 AM
$CELZ https://www.quiverquant.com/news/Creative+Medical+Technology+Holdings%2C+Inc.+Reports+Positive+Interim+Results+from+CELZ-201+Clinical+Trial+for+Chronic+Lower+Back+Pain
0 · Reply
nwest33
nwest33 Jan. 16 at 11:17 PM
$CELZ $IVF Sympathy
0 · Reply
STOCKSGambino
STOCKSGambino Jan. 16 at 10:37 PM
$CELZ https://x.com/StocksGambino/status/2012293109233729763
0 · Reply